对小分子抑制剂的洞察力,这些抑制剂针对细胞外核酸铁酸酶/二酶1的潜在多种人类疾病
Baochan Du1, Jinxiao Ru1, Zixuan Zhan2
1Department of Neurology, Neuro-system and Multimorbidity Laboratory and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
European journal of medicinal chemistry
|March 3, 2024
概括
细胞外核酸铁酸酶/化酶1 (ENPP1) 是骨矿化和癌症的关键. ENPP1 抑制剂在治疗糖尿病和固体瘤等疾病方面表现有前途,目前正在研究它们的结构-活性关系.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞外核酸铁酸酶/化酶1 (ENPP1) 是一种II型的跨膜糖蛋白.
- ENPP1涉及至关重要的生物过程,包括骨矿化,癌细胞增殖和免疫调节.
- ENPP1被认为是各种疾病的重要治疗点.
研究的目的:
- 审查ENPP1.1的结构性质和生物功能.
- 探索ENPP1与实体瘤,糖尿病和无声病等疾病之间的联系.
- 分析ENPP1抑制剂的结构-活性关系,以指导未来的药物开发.
主要方法:
- 对ENPP1的结构,功能和疾病关联的文献综述.
- 对ENPP1抑制剂的临床前数据的分析.
- 对ENPP1抑制剂的结构-活性关系的检查.
主要成果:
- 在骨矿化,癌症和免疫反应中,ENPP1起着至关重要的作用.
- 有限的临床阶段的ENPP1抑制剂用于固体瘤,糖尿病和无声.
- 临床前研究表明,小分子ENPP1抑制剂的治疗效果和安全性是有前途的.
结论:
- 对于多种疾病来说,ENPP1是一个有前途的治疗标.
- 对ENPP1抑制剂的结构-活性关系的进一步研究对于开发有效的治疗方法至关重要.
- ENPP1 抑制剂具有治疗固体瘤,糖尿病和无声的潜力.
相关概念视频
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
157
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
157
ATP Synthase: Mechanism
14.6K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.6K


